Monthly monitoring no longer required for ranibizumab

Article

Monthly monitoring is no longer required for patients taking ranibizumab (Lucentis, Novartis) for a condition that is stable, due to a change in the drug's licence.

Monthly monitoring is no longer required for patients taking ranibizumab (Lucentis, Novartis) for a condition that is stable, due to a change in the drug's licence.

The change comes in the wake of evidence that treatment requirements vary from patient to patient. The drug is approved for the treatment of neovascular age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion, visual impairment due to diabetic macular oedema, and visual impairment due to choroidal neovascularization secondary to pathologic myopia.

"We are pleased to be providing this new personalized approach across [ranibizumab's] four licensed indications and believe it is the right approach for both patients and clinicians," said Frederic Guerard, managing director, UK and Ireland, Novartis Pharmaceuticals UK Ltd.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.